KR20150129735A - 렙틴 생성의 향상을 위한 비마토프로스트 - Google Patents
렙틴 생성의 향상을 위한 비마토프로스트 Download PDFInfo
- Publication number
- KR20150129735A KR20150129735A KR1020157025059A KR20157025059A KR20150129735A KR 20150129735 A KR20150129735 A KR 20150129735A KR 1020157025059 A KR1020157025059 A KR 1020157025059A KR 20157025059 A KR20157025059 A KR 20157025059A KR 20150129735 A KR20150129735 A KR 20150129735A
- Authority
- KR
- South Korea
- Prior art keywords
- bimatoprost
- administered
- bimatoflost
- leptin
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 title claims abstract description 58
- 229960002470 bimatoprost Drugs 0.000 title claims abstract description 54
- 102000016267 Leptin Human genes 0.000 title claims abstract description 22
- 108010092277 Leptin Proteins 0.000 title claims abstract description 22
- 229940039781 leptin Drugs 0.000 title claims abstract description 22
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 title claims abstract description 22
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 11
- 229940002612 prodrug Drugs 0.000 claims abstract description 6
- 239000000651 prodrug Substances 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims description 57
- 235000019789 appetite Nutrition 0.000 claims description 10
- 241000282414 Homo sapiens Species 0.000 claims description 9
- 230000036528 appetite Effects 0.000 claims description 9
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 9
- 230000004580 weight loss Effects 0.000 claims description 9
- 230000000699 topical effect Effects 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 150000002632 lipids Chemical class 0.000 claims description 7
- 210000004027 cell Anatomy 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 239000002243 precursor Substances 0.000 claims description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 5
- 210000000577 adipose tissue Anatomy 0.000 claims description 4
- 238000011200 topical administration Methods 0.000 claims description 4
- 208000031773 Insulin resistance syndrome Diseases 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 230000004069 differentiation Effects 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 208000030159 metabolic disease Diseases 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 2
- 208000016097 disease of metabolism Diseases 0.000 claims description 2
- 210000000229 preadipocyte Anatomy 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 abstract description 3
- 238000011282 treatment Methods 0.000 description 15
- 235000005911 diet Nutrition 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 10
- 230000037213 diet Effects 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 8
- 208000016261 weight loss Diseases 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 230000009467 reduction Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical group CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000007933 dermal patch Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 210000004003 subcutaneous fat Anatomy 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940112534 lumigan Drugs 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- ISZJXIYRLAGBMH-IQMDKZJJSA-N CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1.CCNC(=O)CCC\C=C/CC1C(O)CC(O)[C@@H]1\C=C\C(O)CCc1ccccc1 Chemical compound CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1.CCNC(=O)CCC\C=C/CC1C(O)CC(O)[C@@H]1\C=C\C(O)CCc1ccccc1 ISZJXIYRLAGBMH-IQMDKZJJSA-N 0.000 description 1
- 102000012004 Ghrelin Human genes 0.000 description 1
- 101800001586 Ghrelin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- -1 by topical Chemical class 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000001916 dieting Nutrition 0.000 description 1
- 230000037228 dieting effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000009144 enzymatic modification Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 229930195027 lapatin Natural products 0.000 description 1
- 229940040553 latisse Drugs 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000009063 long-term regulation Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 235000015263 low fat diet Nutrition 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000003880 negative regulation of appetite Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361793132P | 2013-03-15 | 2013-03-15 | |
| US61/793,132 | 2013-03-15 | ||
| PCT/US2014/026110 WO2014143629A1 (en) | 2013-03-15 | 2014-03-13 | Bimatoprost for enhancement of leptin production |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20150129735A true KR20150129735A (ko) | 2015-11-20 |
Family
ID=50442712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020157025059A Withdrawn KR20150129735A (ko) | 2013-03-15 | 2014-03-13 | 렙틴 생성의 향상을 위한 비마토프로스트 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20140275272A1 (enExample) |
| EP (1) | EP2968361A1 (enExample) |
| JP (1) | JP2016513647A (enExample) |
| KR (1) | KR20150129735A (enExample) |
| CN (1) | CN105338985A (enExample) |
| AU (1) | AU2014228307A1 (enExample) |
| BR (1) | BR112015021859A2 (enExample) |
| CA (1) | CA2901529A1 (enExample) |
| HK (1) | HK1220385A1 (enExample) |
| RU (1) | RU2015134772A (enExample) |
| WO (1) | WO2014143629A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2983942A1 (en) | 2015-04-30 | 2016-11-03 | Allergan, Inc. | Cosmetic method and therapeutic use for fat reduction |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| EP0495421B1 (en) | 1991-01-15 | 1996-08-21 | Alcon Laboratories, Inc. | Use of carrageenans in topical ophthalmic compositions |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| US5688819A (en) | 1992-09-21 | 1997-11-18 | Allergan | Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| US7666912B2 (en) * | 2006-03-23 | 2010-02-23 | Massachusetts Eye And Ear Infirmary | Compositions and methods for reducing body fat |
| WO2010100656A2 (en) * | 2009-02-20 | 2010-09-10 | Micro Labs Limited | Storage stable prostaglandin product |
| CA2866067C (en) * | 2011-01-19 | 2015-04-21 | Topokine Therapeutics, Inc. | Uses of certain f-series prostaglandin analogs for treating diabetes and dyslipidemia |
-
2014
- 2014-03-13 CA CA2901529A patent/CA2901529A1/en not_active Abandoned
- 2014-03-13 CN CN201480012846.5A patent/CN105338985A/zh active Pending
- 2014-03-13 WO PCT/US2014/026110 patent/WO2014143629A1/en not_active Ceased
- 2014-03-13 EP EP14716168.1A patent/EP2968361A1/en not_active Withdrawn
- 2014-03-13 JP JP2016502054A patent/JP2016513647A/ja active Pending
- 2014-03-13 US US14/209,099 patent/US20140275272A1/en not_active Abandoned
- 2014-03-13 BR BR112015021859A patent/BR112015021859A2/pt active Search and Examination
- 2014-03-13 AU AU2014228307A patent/AU2014228307A1/en not_active Abandoned
- 2014-03-13 HK HK16108521.3A patent/HK1220385A1/zh unknown
- 2014-03-13 RU RU2015134772A patent/RU2015134772A/ru not_active Application Discontinuation
- 2014-03-13 KR KR1020157025059A patent/KR20150129735A/ko not_active Withdrawn
-
2015
- 2015-11-25 US US14/952,208 patent/US20160310505A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20160310505A1 (en) | 2016-10-27 |
| US20140275272A1 (en) | 2014-09-18 |
| EP2968361A1 (en) | 2016-01-20 |
| RU2015134772A (ru) | 2017-04-21 |
| JP2016513647A (ja) | 2016-05-16 |
| RU2015134772A3 (enExample) | 2018-03-21 |
| CA2901529A1 (en) | 2014-09-18 |
| HK1220385A1 (zh) | 2017-05-05 |
| CN105338985A (zh) | 2016-02-17 |
| BR112015021859A2 (pt) | 2017-07-18 |
| WO2014143629A1 (en) | 2014-09-18 |
| AU2014228307A1 (en) | 2015-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101954869B1 (ko) | 탈모증 치료제 | |
| EP2076269A2 (en) | Formulations for treatment of adipose tissue, cutaneous tissue and disorders, and muscular tissue | |
| BR112012001491B1 (pt) | Preparação terapêutica para tratar dermatite e uso de uma preparação terapêutica | |
| WO2016013551A1 (ja) | 外用組成物 | |
| FR2855753A1 (fr) | Composition a base de diosgenine applicable par voie topique | |
| JP6006940B2 (ja) | 医学的美容脂肪萎縮方法 | |
| JP6796601B2 (ja) | 脂肪を低減させるための美容上の方法及び治療用途 | |
| US9968626B2 (en) | Method for treating obesity | |
| EP1448208B1 (fr) | Composition a base d'ester de diosgenine applicable par voie topique | |
| CN1960723B (zh) | 烷基呋喃在制备用于治疗肥胖症的药物中的用途 | |
| US9907782B2 (en) | Treatment or prevention of seborrheic keratosis using artemisinin and derivatives thereof | |
| KR20150129735A (ko) | 렙틴 생성의 향상을 위한 비마토프로스트 | |
| EP2692332B1 (en) | Composition for the treatment of callus, corns and psoriasis | |
| US10960011B2 (en) | Compositions for the treatment of ischemic ulcers and stretch marks | |
| TW201138850A (en) | Novel topical corticosteroid formulation | |
| US20190365735A1 (en) | Compositions and methods for treating varicose veins | |
| RU2457834C1 (ru) | Способ лечения метаболического синдрома | |
| EP2253228B1 (en) | Composition for controlling and improving female and male gametogenesis | |
| EP3727359B1 (en) | Treatment of fibrosis with inositol | |
| US20140274985A1 (en) | Systemic administration of androgen in treating dry eye syndrome | |
| TW202335679A (zh) | 山竹果殼萃取物用於製備促進糖尿病傷口癒合的藥物的用途 | |
| TW202131927A (zh) | 睾固酮組合物 | |
| CN111491630A (zh) | 糖尿病足溃疡的治疗方法 | |
| CN107814823A (zh) | 一种治疗糖尿病的化合物及其应用 | |
| JP2007332048A (ja) | アクアポリン５の発現亢進剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20150911 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |